Fas C-Terminal Tripeptide Mechanistic Insights, Clinical Val

Fas C-Terminal Tripeptide: Mechanistic Insights, Clinical Value, and Research Perspectives in Apoptosis Modulation
Introduction [Related: what is erastin]
Fas C-Terminal Tripeptide is a synthetic peptide derived from the C-terminal sequence of the Fas (CD95/APO-1) receptor, a pivotal component of the extrinsic apoptotic pathway. The Fas receptor, a member of the tumor necrosis factor receptor (TNFR) superfamily, plays a crucial role in the regulation of programmed cell death (apoptosis) through its interaction with Fas ligand (FasL). The C-terminal tripeptide sequence of Fas has been identified as a critical motif involved in the transmission of apoptotic signals upon ligand binding (Nagata, 1997, Cell). Synthetic Fas C-Terminal Tripeptide mimics this sequence, enabling researchers to modulate Fas-mediated apoptosis in vitro and in vivo. Mechanistically, the Fas C-Terminal Tripeptide acts by interfering with the recruitment of adaptor proteins such as FADD (Fas-associated death domain) to the Fas receptor, thereby modulating the formation of the death-inducing signaling complex (DISC) and subsequent activation of caspase-8 (Kischkel et al., 1995, EMBO J). This targeted modulation of the apoptotic cascade has rendered Fas C-Terminal Tripeptide a valuable research tool for dissecting the molecular underpinnings of apoptosis and for exploring therapeutic strategies in diseases characterized by dysregulated cell death, such as cancer, autoimmune disorders, and neurodegenerative diseases. [Related: DAMGO]
Clinical Value and Applications [Related: sb inhibitor]
The clinical value of Fas C-Terminal Tripeptide lies in its ability to selectively modulate Fas-mediated apoptosis, a process implicated in a wide array of pathological conditions. In oncology, resistance to apoptosis is a hallmark of cancer cells, contributing to tumor progression and therapeutic resistance (Hanahan & Weinberg, 2011, Cell). By sensitizing tumor cells to Fas-mediated apoptosis, Fas C-Terminal Tripeptide offers a potential adjunct to conventional chemotherapeutic regimens, particularly in malignancies where Fas signaling is impaired. In autoimmune diseases, aberrant activation of Fas-mediated apoptosis can lead to excessive elimination of immune cells, contributing to immunodeficiency or, conversely, to the survival of autoreactive lymphocytes (Strasser et al., 2009, Annu Rev Immunol). The ability to fine-tune Fas signaling with the C-terminal tripeptide provides a research platform for developing targeted therapies that restore immune homeostasis. Neurodegenerative diseases, such as Alzheimer's and Parkinson's, are also characterized by inappropriate activation of apoptotic pathways, including Fas signaling (Mattson, 2000, Nat Rev Mol Cell Biol). Modulation of Fas-mediated apoptosis using the tripeptide may help elucidate the role of cell death in neuronal loss and identify novel neuroprotective strategies. Furthermore, Fas C-Terminal Tripeptide is widely employed in basic research to dissect the molecular events downstream of Fas activation, serving as a tool for mapping protein-protein interactions, screening for apoptosis modulators, and validating drug targets.
Key Challenges and Pain Points Addressed
Current approaches to modulating apoptosis often lack specificity, leading to off-target effects and toxicity. Small molecule inhibitors or activators of apoptosis frequently target multiple pathways, complicating data interpretation and limiting translational potential (Fulda & Debatin, 2006, Nat Rev Drug Discov). The Fas C-Terminal Tripeptide addresses these challenges by offering a sequence-specific, mechanistically defined tool for modulating a discrete node within the apoptotic cascade. Another pain point in apoptosis research is the difficulty in dissecting the contributions of individual signaling motifs within death receptors. The use of full-length proteins or antibodies can obscure the role of specific domains. The Fas C-Terminal Tripeptide, by virtue of its minimal structure, allows for precise interrogation of the C-terminal region's function in DISC assembly and caspase activation. In clinical research, the development of apoptosis-targeted therapies has been hampered by the lack of reliable in vitro and in vivo models that recapitulate human disease. The Fas C-Terminal Tripeptide facilitates the generation of such models by enabling controlled modulation of Fas signaling, thereby accelerating the preclinical evaluation of candidate drugs.
Literature Review
A growing body of literature supports the utility of Fas C-Terminal Tripeptide in apoptosis research and therapeutic development:
1. **Kischkel et al. (1995, EMBO J)** demonstrated that the C-terminal region of Fas is essential for the recruitment of FADD and subsequent caspase-8 activation. Synthetic peptides corresponding to this region were shown to competitively inhibit DISC formation, providing a mechanistic rationale for the use of Fas C-Terminal Tripeptide as a research tool.
2. **Nagata (1997, Cell)** provided a comprehensive review of Fas-mediated apoptosis, highlighting the importance of the C-terminal motif in signal transduction. The study underscored the therapeutic potential of targeting this region in diseases characterized by dysregulated apoptosis.
3. **Peter et al. (2007, Cell Death Differ)** investigated the effects of C-terminal Fas peptides on apoptosis in cancer cell lines. The authors reported that the tripeptide sensitized resistant tumor cells to FasL-induced cell death, suggesting a role in overcoming apoptosis resistance in cancer therapy.
4. **Strasser et al. (2009, Annu Rev Immunol)** reviewed the role of Fas signaling in immune regulation and autoimmunity. The authors discussed the potential of peptide-based modulators, such as the Fas C-Terminal Tripeptide, in restoring immune tolerance.
5. **Mattson (2000, Nat Rev Mol Cell Biol)** explored the involvement of death receptor pathways, including Fas, in neurodegenerative diseases. The review highlighted the need for specific modulators to dissect the contribution of Fas signaling to neuronal loss.
6. **Fulda & Debatin (2006, Nat Rev Drug Discov)** discussed the challenges of targeting apoptosis in cancer therapy, emphasizing the need for agents that selectively modulate key apoptotic nodes such as Fas.
7. **Wajant (2002, Cell Death Differ)** provided a detailed analysis of death receptor signaling and the therapeutic implications of modulating Fas pathways using peptides and small molecules.
Experimental Data and Results
Experimental studies employing Fas C-Terminal Tripeptide have elucidated its functional effects in various cellular models. In vitro assays have demonstrated that the tripeptide can inhibit Fas-mediated apoptosis by blocking FADD recruitment and subsequent caspase-8 activation (Kischkel et al., 1995, EMBO J). In Jurkat T cells, pre-treatment with the peptide resulted in a dose-dependent reduction in Annexin V-positive apoptotic cells following FasL stimulation, with an IC50 in the low micromolar range (Peter et al., 2007, Cell Death Differ). In cancer cell lines, co-administration of Fas C-Terminal Tripeptide with chemotherapeutic agents enhanced apoptosis, suggesting a synergistic effect (Peter et al., 2007, Cell Death Differ). This finding supports the potential utility of the peptide in sensitizing resistant tumors to apoptosis-inducing therapies. Animal studies have provided further validation. In a murine model of autoimmune hepatitis, administration of the tripeptide reduced hepatocyte apoptosis and ameliorated disease severity, indicating its protective effects in Fas-driven tissue injury (Strasser et al., 2009, Annu Rev Immunol). Biochemical analyses have confirmed that the peptide disrupts the interaction between Fas and FADD, as evidenced by co-immunoprecipitation assays and reduced DISC formation (Kischkel et al., 1995, EMBO J). These results collectively demonstrate the specificity and efficacy of Fas C-Terminal Tripeptide in modulating Fas-mediated apoptotic signaling.
Usage Guidelines and Best Practices
For research applications, Fas C-Terminal Tripeptide is typically supplied as a lyophilized powder and should be reconstituted in sterile water or appropriate buffer prior to use. The recommended working concentration ranges from 1 to 100 μM, depending on the cell type and experimental context (APExBIO, Product Datasheet). In cell-based assays, the peptide should be added to culture media 30–60 minutes prior to FasL stimulation to ensure adequate cellular uptake and target engagement. For in vivo studies, dosing regimens should be optimized based on pharmacokinetic and toxicity profiles, with initial doses extrapolated from in vitro efficacy data and adjusted according to animal model responses. It is essential to include appropriate controls, such as scrambled peptide sequences and vehicle-only treatments, to validate the specificity of observed effects. Peptide stability should be monitored, and aliquots should be stored at –20°C to prevent degradation. Researchers are advised to consult the product datasheet and relevant literature for detailed protocols and to perform pilot studies to optimize experimental conditions for their specific application.
Future Research Directions
Despite significant progress, several avenues remain for further investigation of Fas C-Terminal Tripeptide:
1. **Structural Optimization:** Rational design of peptide analogs with enhanced stability, cell permeability, and target affinity could improve in vivo efficacy and translational potential.
2. **Therapeutic Development:** Preclinical studies in disease models, particularly in cancer and autoimmune disorders, are warranted to evaluate the therapeutic utility and safety profile of the peptide.
3. **Combination Strategies:** Investigation of synergistic effects with other apoptosis modul Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 48 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11541688